Blood Cholesterol
Conditions
Keywords
cholesterol, Bokbunja, Clinical Trial
Brief summary
This study was conducted to investigate the effects of daily supplementation of unripe Bokbunja extract on improvement of blood cholesterol.
Detailed description
This study was a 12 weeks, randomized, double-blind, placebo-controlled human trial. Forty subjects were randomly divided into unripe Bokbunja extract 600 mg or placebo group. The investigators measured total cholesterol, lipid profile, arteriosclerosis index, anthropometric index, oxidized LDL.
Interventions
DIETARY_SUPPLEMENTunripe Bokbunja Extract
tablet(1 tablet/d, 600 mg/d) for 12 weeks
DIETARY_SUPPLEMENTPlacebo
Placebo for 12 weeks
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* age between 20 and 65 years, * Total cholesterol 200-239 mg/dl * subjects giving written informed consent
Exclusion criteria
* Cardiovascular disease, e.g. arrhythmia, heart failure, myocardial infarction * History of disease that could interfere with the test products or impede their absorption, such as gastrointestinal disease or gastrointestinal surgery * Participation in any other clinical trials within past 2 months * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * Pregnancy or breast feeding etc,.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of Total cholesterol | 12 weeks | Changes of total cholesterol were assessed before and after the intervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes of Lipid profile(total cholesterol, LDL-cholesterol, triglyceride, HDL-cholesterol, free fatty acid, Apolipoprotein A1, Apolipoprotein B, Lipoprotein a, hs-CRP) | 12 weeks | Changes of lipid profile(total cholesterol, LDL-cholesterol, triglyceride, HDL-cholesterol, free fatty acid, Apolipoprotein A1, Apolipoprotein B, Lipoprotein a, hs-CRP) were assessed before and after the intervention |
| Changes of Arteriosclerosis index(total cholesterol/HDL-cholesterol, LDL-cholesterol/HDL-cholesterol, triglyceride/HDL-cholesterol, (total HDL-cholesterol-HDL-cholesterol)/HDL-cholesterol, Apolipoprotein B/Apolipoprotein A1) | 12 weeks | Changes of arteriosclerosis index(total cholesterol/HDL-cholesterol, LDL-cholesterol/HDL-cholesterol, triglyceride/HDL-cholesterol, (total HDL-cholesterol-HDL-cholesterol)/HDL-cholesterol, Apolipoprotein B/Apolipoprotein A1) were assessed before and after the intervention |
| Changes of Anthropometric index(weight, body mass index, waist hip ratio, waist, hip, fat percentage, lean body mass) | 12 weeks | Changes of anthropometric index(weight, body mass index, waist hip ratio, waist, hip, fat percentage, lean body mass) were assessed before and after the intervention |
| Changes of Oxidized LDL | 12 weeks | Changes of oxidized LDL were assessed before and after the intervention |
Outcome results
None listed